245 related articles for article (PubMed ID: 18195360)
1. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Liu J; Nussinov R
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
[TBL] [Abstract][Full Text] [Related]
2. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
3. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
4. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
5. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development.
Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC
Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899
[TBL] [Abstract][Full Text] [Related]
6. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
Illingworth CJ; Loenarz C; Schofield CJ; Domene C
Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
8. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
9. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
11. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
12. Insights into the molecular features of the von Hippel-Lindau-like protein.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
Amino Acids; 2019 Nov; 51(10-12):1461-1474. PubMed ID: 31485743
[TBL] [Abstract][Full Text] [Related]
13. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
[TBL] [Abstract][Full Text] [Related]
14. Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation.
Kim BY; Kim H; Cho EJ; Youn HD
Exp Mol Med; 2008 Feb; 40(1):71-83. PubMed ID: 18305400
[TBL] [Abstract][Full Text] [Related]
15. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and β-catenin regulation.
Shafique S; Rashid S
Prog Biophys Mol Biol; 2019 Aug; 145():65-77. PubMed ID: 30528740
[TBL] [Abstract][Full Text] [Related]
17. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein.
Bex C; Knauth K; Dambacher S; Buchberger A
Nucleic Acids Res; 2007; 35(21):e142. PubMed ID: 17986458
[TBL] [Abstract][Full Text] [Related]
18. Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
Minervini G; Mazzotta GM; Masiero A; Sartori E; Corrà S; Potenza E; Costa R; Tosatto SC
Sci Rep; 2015 Jul; 5():12605. PubMed ID: 26211615
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
20. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
